Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences
Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences
Philadelphia, PA — Audacity Therapeutics, a Public Benefit Pharmaceutical Company, announced today it has been selected to present at the upcoming Cavendish BioHealth Impact Forum taking place June 19, 2019 in Chicago, Ill., co-hosted with the Shirley Ryan AbilityLab, Envestnet and IQVIA. The Forum provides an environment for family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.
J. Michael Moffat, Chairman of Cavendish Global explains, “With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. Audacity Therapeutics’ founders are highly seasoned drug developers whose novel business model features lowered pressure on maximizing ROI, so that the company can capture a huge opportunity by leveraging the vast landscape of already existing, high medical impact drugs, that don’t meet the ROI requirements of traditional companies.”
“We are honored to be selected to present at the 2019 Chicago Forum, where we look forward to sharing examples of the ‘passed over’ therapies that could be treating patients today were it not for the limitations of our industry’s financial model. An example is a generic drug that works very differently than the current immune modulating drugs for Multiple Sclerosis” said Barbara Handelin, CEO. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who share our vision: to deliver high medical impact, sustainably priced medicines.”
The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by those actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.
About Audacity Therapeutics
http://audacitytherapeutics.
Audacity Therapeutics is a team of six seasoned drug developers, entrepreneurs and inventors that bring a history of highly innovative FDA/EMA approved products and a commitment to running a thriving business serving the public health. We are innovating every aspect of running a pharmaceutical business – from a profit balanced portfolio, to reducing research costs, to collaborating rather than competing in a new “Public Benefit Pharmaceutical” economy.
The company was created to serve all patients who lack effective treatment for serious conditions - recognizing that this applies to most people. Our promise: make high medical impact, sustainably priced drugs. Our principles of operation include integrating patients into all we do, being practical in solving medical problems with sensible solutions and practicing transparency so that the R&D world can benefit from all our learnings.
For Further Information, contact:
Barbara Handelin, PhD
CEO
Audacity Therapeutics, PBC
bhandelin@
About Cavendish Global
Cavendish Global is a peer-to-peer community of individually-selected innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace — through connectivity, advisory services, access to key opinion leaders and capital opportunities. The upcoming BioHealth Impact Forum will take place June 19, 2019 at the Shirley Ryan AbilityLab, and is by invitation only. Throughout 2019 and early 2020, Cavendish will host Forums in Phoenix, Ariz., San Francisco, Calif., New York City and additional cities to be announced.
Learn more about the upcoming Chicago Forum at http://cavendishglobal.com/
For Further Information, Contact:
Ian Kenyon
Senior Vice President, Cavendish Global
